Opthea (OPT) Stock Price, News & Analysis

Company Overview

Opthea Limited (NASDAQ:OPT) is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal vascular diseases. The company’s lead product candidate, OPT-302, is designed to inhibit vascular endothelial growth factors C and D (VEGF-C/D) and is being evaluated as a potential treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s research strategy aims to complement existing anti-VEGF-A therapies by providing a broader blockade of the VEGF family to address residual vision loss in patients receiving standard care.

OPT-302 has advanced through multiple clinical trials, including a Phase 2b study in wet AMD patients and a Phase 1/2 trial in DME patients. Data from these trials have demonstrated promising safety and efficacy signals, including improvements in visual acuity and reductions in retinal fluid. Opthea collaborates with global contract research organizations and ophthalmology centers to support its clinical development program, with ongoing studies designed to establish optimal dosing regimens and confirm long-term benefits.

Founded in 2009 based on research conducted at the Walter and Eliza Hall Institute in Melbourne, Opthea is headquartered in Melbourne, Australia, with strategic operations in North America. The company’s management team combines expertise in ophthalmology, clinical development, regulatory affairs and commercialization to advance its pipeline toward potential regulatory approvals. Opthea is committed to addressing unmet medical needs in retinal diseases and to creating value for patients, healthcare providers and investors through its innovative therapeutic approach.

Key Stats

• Today's Range: $3.41 to $3.41
• 50-Day Range: $3.41 to $3.41
• 52-Week Range: $1.79 to $6.30
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $524.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Opthea Stock Analysis - MarketRank™

Opthea scored higher than 1% of companies evaluated by MarketBeat, and ranked 864th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Opthea has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Opthea has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Opthea are expected to grow in the coming year, from ($1.39) to ($0.67) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OPT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Opthea does not currently pay a dividend.

Dividend Growth

Opthea does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for OPT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Opthea insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.20% of the stock of Opthea is held by insiders.

Percentage Held by Institutions

55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 5/25/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OPT
• CIK: 1815620
• Web: www.opthea.com
• Phone: 61-3-9826-0399
• Fax: N/A
• Employees: 8
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: $25 thousand
• Price / Sales: 20,993.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.31) per share
• Price / Book: -2.60

Miscellaneous

• Outstanding Shares: 153,911,000
• Free Float: 165,525,000
• Market Cap: $524.84 million
• Optionable: Not Optionable
• Beta: 1.12